Literature DB >> 3087438

DDAVP infusion in five patients with type Ia glycogen storage disease and associated correction of prolonged bleeding times.

G E Marti, M E Rick, J Sidbury, H R Gralnick.   

Abstract

Five patients with glycogen storage disease type I (GSD-I) were evaluated for a bleeding diathesis and subsequently were given an infusion of 1-deamino-8-D-arginine vasopressin (DDAVP). Although platelet counts were normal or slightly elevated, the baseline template bleeding times were prolonged in four of the patients. Prothrombin times and activated partial thromboplastin times were normal, while ADP- and epinephrine-induced platelet aggregations were absent in the three patients tested. Ristocetin- and collagen-induced platelet aggregations were abnormal. Laurell and immunoradiometric determinations of the factor VIII-related antigen (vWf antigen) were decreased. Glyoxyl agarose gel electrophoresis of the patients' plasma revealed abnormal multimer patterns in four of the five patients. After the DDAVP infusion the platelet aggregation abnormalities persisted; however, the bleeding time and the von Willebrand antigen and activity corrected. We conclude that GSD-Ia patients may have a metabolically acquired form of von Willebrand's syndrome as well as an acquired intrinsic platelet defect, and that DDAVP may be useful in the management of bleeding in these patients.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3087438

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  4 in total

1.  Perioperative management of hemostasis for surgery of benign hepatic adenomas in patients with glycogen storage disease type ia.

Authors:  Alix Mollet-Boudjemline; Aurélie Hubert-Buron; Catherine Boyer-Neumann; Roxana Aldea; Dominique Franco; Pascale Trioche-Eberschweiller; Anne-Elisabeth Mas; Mylène Mabille; Philippe Labrune; Vincent Gajdos
Journal:  JIMD Rep       Date:  2011-06-22

Review 2.  Desmopressin (DDAVP) and hemostasis.

Authors:  S Lethagen
Journal:  Ann Hematol       Date:  1994-10       Impact factor: 3.673

3.  Acquired von Willebrand's disease.

Authors:  B J Hennessy; B White; M Byrne; O P Smith
Journal:  Ir J Med Sci       Date:  1998 Apr-Jun       Impact factor: 1.568

4.  Decreased plasma concentration of von Willebrand factor antigen (VWF:Ag) in patients with glycogen storage disease type Ia.

Authors:  C Mühlhausen; R Schneppenheim; U Budde; M Merkel; N Muschol; K Ullrich; R Santer
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.750

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.